Production (Stage)
Inhibrx Biosciences, Inc.
INBX
$14.39
$0.473.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -93.88% | -- | 233.33% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -93.88% | -- | 233.33% | -100.00% |
| Cost of Revenue | -70.04% | -59.35% | 2.20% | 98.30% | -88.79% |
| Gross Profit | 70.04% | 58.65% | -2.52% | -98.18% | 88.78% |
| SG&A Expenses | -39.60% | -759.31% | 0.19% | 1,185.50% | 55.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.89% | -120.06% | 1.85% | 289.18% | 68.62% |
| Operating Income | 41.89% | 120.55% | -2.12% | -289.22% | -68.68% |
| Income Before Tax | 44.97% | 48.87% | 15.30% | 4,049.27% | -60.91% |
| Income Tax Expenses | -- | 100.00% | -- | -60.00% | -- |
| Earnings from Continuing Operations | 44.97% | 48.86% | 15.30% | 4,048.85% | -60.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.97% | 48.86% | 15.30% | 4,048.85% | -60.91% |
| EBIT | 41.89% | 120.55% | -2.12% | -289.22% | -68.68% |
| EBITDA | 42.52% | 121.40% | -1.13% | -290.84% | -69.00% |
| EPS Basic | 51.48% | 55.27% | 35.45% | 3,047.28% | -28.51% |
| Normalized Basic EPS | 51.48% | 118.88% | 35.45% | -159.36% | -28.51% |
| EPS Diluted | 51.48% | 55.25% | 35.36% | 3,009.82% | -28.51% |
| Normalized Diluted EPS | 51.48% | 118.88% | 35.45% | -156.07% | -28.51% |
| Average Basic Shares Outstanding | 13.41% | 14.33% | 31.22% | 33.98% | 25.21% |
| Average Diluted Shares Outstanding | 13.41% | 14.33% | 31.22% | 35.71% | 25.21% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |